Cerebrovascular effects of galantamine treatment in patients with Alzheimer's disease.

Cerebrovascular effects of galantamine treatment in patients with Alzheimer's disease. - Cerebrovascular effects of galantamine

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29762

Enrollment

Registered

2006-11-10

Start date

2007-01-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dementia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: meeting DSM IV-R criteria for dementia meeting NINCDS-ADRDA criteria for probable AD clinical dementia rating scale (CDR) of 0.5 to 1.5

Exclusion criteria

Exclusion criteria: contra-indication for or unwilling to receive treatment with cholinesterase inhibitors major cerebrovascular disease (stroke)

Design outcomes

Primary

Measure	Time frame
Cerebral perfusion: - changes in cerebral blood flow during treatment with ChEIs versus placebo - changes in dynamic cerebral autoregulation during treatment with ChEIs versus placebo.	—

Secondary

Measure	Time frame
Progression of cerebrovascular lesions and changes in neuropsychological functioning. Evaluation of early-dose responses in CBF to ChEI treatment.	—

Countries

Netherlands

Outcome results